2019台湾专家共识声明_他汀类药物不耐受.pdfVIP

+ MODEL Journal of the Formosan Medical Association xxx (xxxx) xxx Available online at ScienceDirect journal homepage: Review Article 2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance Shih-Chieh Chien a,1, Po-Sheng Chen b,c,1, Yi-Hsiang Huang d,e, Sung-Chun Tang f, Yi-Heng Li b,*, Hung-I Yeh g,h,** a Department of Critical Care Medicine, MacKay Memorial Hospital, Taipei, Taiwan b Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan c Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan d Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan e Institute of Clinical Medicine, National Yang Ming University School of Medicine, Taipei, Taiwan f Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan g Departments of Internal Medicine and Medical Research, MacKay Memorial Hospital, Taipei, Taiwan h Department of Medicine, Mackay Medical College, New Taipei City, Taiwan Received 28 July 2018; received in revised form 6 November 2018; accepted 30 November 2018 KEYWORDS Statin reduces low-density lipoprotein cholesterol and improves clinical outcomes in high risk pa- Statin; tients. In general, statin is a safe and well-tolerated medication. However, varieties of adverse Side effect; effects are reported in some patients and may interfere long-term drug compliance. Statin- Consensus associated muscle events and liver function change account for most of these